Florian I. Schmidt Lab

SARS-CoV-2 Neutralizing NANOBODIES® Molecules

Project details

In a joint project with the Core Facility NANOBODY^Ⓡ at the University of Bonn, we have generated SARS-CoV-2 neutralizing NANOBODY^Ⓡ molecules to study mechanistic aspects of virus fusion and to develop novel antiviral biologics. While we continue to investigate basic research aspects of SARS-CoV-2 infection and fusion with NANOBODY^Ⓡ technology, the clinical development of antiviral SARS-CoV-2 NANOBODY^Ⓡ molecules is pursued by the spin-out company DiosCURE Therapeutics SE (Link: https://www.dioscure.com/company) of the University of Bonn.

‍

Project-related publications

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Koenig PA, Das H, Liu H, Kümmerer BM, Gohr FN, Jenster LM, Schiffelers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, Gatterdam K, Ruetalo N, Christensen MH, Fandrey CI, Normann S, Tödtmann JMP, Pritzl S, Hanke L, Boos J, Yuan M, Zhu X, Schmid-Burgk JL, Kato H, Schindler M, Wilson IA, Geyer M, Ludwig KU, Hällberg BM, Wu NC, Schmidt FI.